NCT05413135Phase 2Completed

Study of ARO-APOC3 in Adults With Dyslipidemia

Study sponsor: Arrowhead Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-22Actual
Enrollment · participants418Actual
Source updated2026-11-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Time frame: Through 24 months. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Description: An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs that started on or after the first dose date of study drug. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. Time frame: Baseline through Month 24.

Check registry source

· 1 field changed

Primary completion date changed

Before: 18 Sep 2025. After: 22 Sep 2025.

Check registry source

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2025. After: 18 Sep 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview